Seeking AlphaCodex · 实盘不做把握 6/10
北京时间·🕒 发布 00:27:57时区推断·⟳ 抓取 00:29:31·⚡ 决策 07-24 00:30:56 +1m25s·95.7 天前
罗氏上半年业绩基本符合预期并重申2026年指引，股价已在苏黎世上涨约5%
罗氏上半年收入和利润大体符合预期，核心新增信息是外汇调整后利润好于预期和管理层称接近指引高端，但公司仍只是重申全年指引。
📄 原文Seeking Alpha↗ 原文
Roche jumps despite reiterating 2026 outlook
Roche (RHHBY) (RHHBF) shares closed ~5% higher in Zurich on Thursday, recording its best single-day gain since November…
不做 罗氏（RHHBY.US）
财报基本符合预期且仅重申指引，瑞士本地股价已约+5%反应，盘中追ADR没有明确剩余edge。
不做 罗氏（RHHBF.US）
同一事件已在主上市市场充分反应，且缺少指引上修或新药重大进展，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 medium · price-in 风险 high ↗
关键理由
- 罗氏上半年收入和利润大体符合预期，核心新增信息是外汇调整后利润好于预期和管理层称接近指引高端，但公司仍只是重申全年指引。
- 该信号正文已说明苏黎世股价当日收涨约5%，主要反应窗口已发生，盘中追美股ADR缺乏未定价增量。
- 罗氏为超大市值制药公司，未披露新的药品获批、重大订单、并购或指引上修，事件不足以形成短线高弹性交易。
主要风险
- 若后续公司正式上调全年指引或披露超预期管线进展，需要作为新催化重新评估。
原文全文
展开原文 · 1,780 字
Roche (RHHBY) (RHHBF) shares closed ~5% higher in Zurich on Thursday, recording its best single-day gain since November, even as the Swiss drugmaker reaffirmed its 2026 outlook with its financials for the first half of the year.
The pharma giant recorded CHF 30.36B of revenue for H1 2026 with a 2% YoY decline, roughly in line with analysts’ expectations of CHF 30.31B, according to Reuters data. Its core operating profit also fell ~1% YoY to CHF 11.86B, but, on a forex-adjusted basis, rose ~10% YoY, topping Street forecasts.
The lackluster performance on a local currency basis was mainly due to appreciation of the Swiss franc against many foreign currencies, notably the USD, the company said, adding that demand for its pharmaceutical and diagnostic products drove topline growth.
Sales in Roche’s (RHHBF) Diagnostics unit fell ~3% YoY to CHF 6.7B, while its Pharmaceuticals segment added CHF 23.6B with a 1% YoY decline. As for notable products, eye therapy Vabysmo added CHF 2.0B, with ~8% YoY growth on a forex-adjusted basis but missing Street forecasts amid softer U.S. demand.
Multiple sclerosis drug Ocrevus brought in CHF 3.5B with a ~7% YoY growth, and Elevidys gene therapy, marketed with Sarepta Therapeutics (SRPT), added CHF 180M with a ~62% YoY growth.
The company projected a CHF 600M headwind from off-patent versions of its brand-name pharmaceuticals this year compared to the $1B estimate previously but confirmed its growth outlook for 2026.
Roche (RHHBY) continues to estimate its adjusted EPS and sales to grow in a high-single-digit range and a mid-single-digit percentage range this year, respectively. “We’re trending toward the high end of our guidance,” CEO Thomas Schinecker told Bloomberg TV. “But let’s see how it continues” into Q3, he added.
The pharma giant recorded CHF 30.36B of revenue for H1 2026 with a 2% YoY decline, roughly in line with analysts’ expectations of CHF 30.31B, according to Reuters data. Its core operating profit also fell ~1% YoY to CHF 11.86B, but, on a forex-adjusted basis, rose ~10% YoY, topping Street forecasts.
The lackluster performance on a local currency basis was mainly due to appreciation of the Swiss franc against many foreign currencies, notably the USD, the company said, adding that demand for its pharmaceutical and diagnostic products drove topline growth.
Sales in Roche’s (RHHBF) Diagnostics unit fell ~3% YoY to CHF 6.7B, while its Pharmaceuticals segment added CHF 23.6B with a 1% YoY decline. As for notable products, eye therapy Vabysmo added CHF 2.0B, with ~8% YoY growth on a forex-adjusted basis but missing Street forecasts amid softer U.S. demand.
Multiple sclerosis drug Ocrevus brought in CHF 3.5B with a ~7% YoY growth, and Elevidys gene therapy, marketed with Sarepta Therapeutics (SRPT), added CHF 180M with a ~62% YoY growth.
The company projected a CHF 600M headwind from off-patent versions of its brand-name pharmaceuticals this year compared to the $1B estimate previously but confirmed its growth outlook for 2026.
Roche (RHHBY) continues to estimate its adjusted EPS and sales to grow in a high-single-digit range and a mid-single-digit percentage range this year, respectively. “We’re trending toward the high end of our guidance,” CEO Thomas Schinecker told Bloomberg TV. “But let’s see how it continues” into Q3, he added.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。